Hartford Healthcare Fund A (HGHAX)
35.89
-0.17
(-0.47%)
USD |
Mar 04 2025
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| -- | -- | -- | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -- | -- | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. Under normal market and economic conditions, the Fund will invest at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (Wellington Management). |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Hartford Funds |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
--
--
Peer Group Low
--
Peer Group High
1 Year
% Rank:
--
--
Peer Group Low
--
Peer Group High
3 Months
% Rank:
--
--
Peer Group Low
--
Peer Group High
3 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
6 Months
% Rank:
--
--
Peer Group Low
--
Peer Group High
5 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
YTD
% Rank:
--
--
Peer Group Low
--
Peer Group High
10 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of March 05, 2025.
Asset Allocation
As of January 31, 2025.
| Type | % Net |
|---|---|
| Cash | 0.21% |
| Stock | 99.79% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly and Co | 11.97% | 914.99 | 0.43% |
| UnitedHealth Group Inc | 9.51% | 472.52 | -0.44% |
| Boston Scientific Corp | 4.55% | 103.80 | 0.18% |
| Intuitive Surgical Inc | 4.28% | 556.71 | -0.22% |
| Merck & Co Inc | 4.06% | 92.46 | -0.11% |
| Thermo Fisher Scientific Inc | 3.14% | 517.64 | 0.21% |
| Vertex Pharmaceuticals Inc | 2.83% | 487.23 | 0.21% |
| Danaher Corp | 2.81% | 208.72 | 1.37% |
| Cencora Inc | 2.28% | 251.02 | -0.89% |
| Edwards Lifesciences Corp | 2.17% | 71.59 | 0.29% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.25% |
| Actual Management Fee | 0.86% |
| Administration Fee | -- |
| Maximum Front Load | 5.50% |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 2000.00 None |
| Minimum Subsequent Investment | 50.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. Under normal market and economic conditions, the Fund will invest at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (Wellington Management). |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Hartford Funds |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM | -- |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| ROI (TTM) | -- |
| Return on Investment (TTM) | -- |
| Earning Yield | -- |
| LT Debt / Shareholders Equity | -- |
Growth Metrics
| EPS Growth (1Y) | 6.13% |
| EPS Growth (3Y) | 1.19% |
| EPS Growth (5Y) | 7.43% |
| Sales Growth (1Y) | 10.58% |
| Sales Growth (3Y) | 13.13% |
| Sales Growth (5Y) | 13.88% |
| Sales per Share Growth (1Y) | 11.40% |
| Sales per Share Growth (3Y) | 13.48% |
| Operating Cash Flow - Growth Ratge (3Y) | 2.84% |
As of January 31, 2025
Fund Details
| Key Dates | |
| Inception Date | 5/1/2000 |
| Last Annual Report Date | 10/31/2024 |
| Last Prospectus Date | 3/1/2024 |
| Share Classes | |
| HGHCX | C |
| HGHFX | F |
| HGHIX | Inst |
| HGHRX | Retirement |
| HGHSX | Retirement |
| HGHTX | Retirement |
| HGHVX | Retirement |
| HGHYX | Inst |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | -- |
| Leveraged Fund | -- |
| Fund of Funds | No |
| Currency Hedged Fund | -- |
| Synthetic Replication Fund | No |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:HGHAX", "name") |
| Broad Asset Class: =YCI("M:HGHAX", "broad_asset_class") |
| Broad Category: =YCI("M:HGHAX", "broad_category_group") |
| Prospectus Objective: =YCI("M:HGHAX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |